Ligand Design with Accelerated Disulfide Formation with Serum Albumin to Extend Blood Retention

Area of Science:

• Pharmacology
• Biochemistry
• Drug Delivery

Background:

• Short blood half-life of small molecular weight therapeutics limits their efficacy.
• Renal clearance is a primary factor contributing to rapid drug elimination.
• Human serum albumin (HSA) is a potential target for drug half-life extension strategies.

Purpose of the Study:

• To design and evaluate a novel ligand for enhanced binding to human serum albumin (HSA).
• To assess the ligand's ability to prolong the blood half-life of therapeutics in vivo.
• To investigate the mechanism of ligand-HSA interaction for improved drug retention.

Main Methods:

• Synthesis of a novel ligand incorporating an alkyl chain and an activated disulfide.
• In vitro assessment of ligand binding affinity to HSA compared to control ligands.
• In vivo pharmacokinetic studies in mice to determine the ligand's effect on blood half-life.

Main Results:

• The novel ligand demonstrated significantly higher binding to HSA compared to a control ligand.
• In vivo studies showed a 1.6-fold and 9.2-fold increase in half-life compared to controls with only disulfide or alkyl chain, respectively.
• The ligand's dual binding mechanism (hydrophobic interaction and disulfide bond formation) was confirmed.

Conclusions:

• The proposed ligand effectively binds to HSA, prolonging drug half-life.
• This ligand-HSA interaction platform offers a promising strategy for enhancing the in vivo performance of small molecular weight therapeutics.
• The developed ligand has potential applications in optimizing drug delivery and therapeutic outcomes.